Researcher:
Yıldız, Amra Adrovic

Loading...
Profile Picture
ORCID

Job Title

Doctor

First Name

Amra Adrovic

Last Name

Yıldız

Name

Name Variants

Yıldız, Amra Adrovic

Email Address

Birth Date

Search Results

Now showing 1 - 3 of 3
  • Placeholder
    Publication
    The role of S100A12 and Toll-like receptor 4 in assessment of disease activity in familial Mediterranean fever and juvenile idiopathic arthritis
    (Wiley, 2023) Dumur, Seyma; Barut, Kenan; Kasapcopur, Ozgur; Kucur, Mine; N/A; Yıldız, Amra Adrovic; Doctor; Koç University Hospital; N/A
    Objective: Our aim was to investigate the possible relationship between the serum S100A12 and Toll-like receptor 4 (TLR4) levels, and the activity of familial Mediterranean fever (FMF) and juvenile idiopathic arthritis (JIA) in accordance with the routine biochemical parameters. Furthermore, the effectiveness of these 2 biomarkers in distinguishing FMF from JIA has been evaluated. Method: Sixty-nine children with FMF, 68 children with JIA, and 35 healthy children were included in this study. S100A12 and TLR4 levels were measured by the sandwich enzyme-linked immunosorbent assay technique. Results: In the FMF patient group, serum S100A12 level was found to be significantly higher than in both the JIA and control groups (P = .000 and P = .000, respectively). Although S100A12 levels were higher in the attack period compared to the attack-free period, this increase was not statistically significant (P > .05). TLR4 levels were statistically significantly higher in the attack period compared to the attack-free period in children with FMF (P < .05). Although there was no relationship between S100A12 levels and disease activity, there is a clear correlation between S100A12 and the Auto-Inflammatory Disease Activity Index in attack-free FMF patients (r = 0.612 P = .000). Conclusion: Serum S100A12 levels were not found to be a potentially valuable biomarker for assessing disease activity in either FMF or JIA. However, TLR4 levels were found to be a valuable biomarker for assessing disease activity in children with FMF. Further research which includes serial monitoring of S100A12 and TLR4 levels in a large cohort will provide detailed information about accuracy of these 2 potential biomarkers in both patients group.
  • Placeholder
    Publication
    Assessment of the transition of care from pediatric to adult rheumatology in a tertiary center
    (Wiley, 2022) Ugurlu, Serdal; Ayla, Ali Yagiz; Besiroglu, Helin Idil; Azman, Feyza Nur; Egeli, Bugra; Eren, Hatice; Durucan, Ibrahim; Alkan, Arif; Ozturk, Sila; Ergun, Sercan; Barut, Kenan; Haslak, Fatih; Sahin, Sezgin; Yildiz, Mehmet; Ozdogan, Huri; Kasapcopur, Ozgur; N/A; Yıldız, Amra Adrovic; Doctor; N/A; Koç University Hospital; N/A
    Background/Purpose: Taking the responsibility for their own health should be an important goal for the patients in the health care transition process. The Transition Readiness Assessment Questionnaire (TRAQ) is an effective tool to assess the competencies of the patients in five domains, which is usually administered before transitioning to adult care. For the first time, we aimed to measure the self-management skills of the patients with rheumatologic diseases who had already transitioned to adult rheumatology by using the TRAQ. Methods: 310 patients who had transitioned from pediatric to adult rheumatology between June 2020-June 2021 were interviewed. The TRAQ was administered to the patients by the physicians in our clinic. The patients were divided into groups according to their diagnoses. The patients with two rheumatologic diagnoses in different categories were included in both groups. The data evaluated included sex, age at diagnosis, age at transition to adult care, age at TRAQ administration, and diagnoses of the patients. Results: There were 184 female (59.4%) and 126 male (40.6%) patients. The mean age at diagnosis, the mean transition age and the mean age when the TRAQ was administered were 10.7 ± 4.29, 21.1 ± 1.69 and 24.0 ± 2.26 years, respectively. The minimum and maximum ages of transition were 16 and 26, respectively (IQR:20-22). 22 patients were in the 16-18 age group, 170 patients were in the 19-21 age group, and 118 patients were in the 22+ age group according to the transition age. The patients consisted of four groups: FMF (n=203), arthritis (JIA and juvenile SpA, n=81), connective tissue disorders (SLE, scleroderma, polymyositis, dermatomyositis and Sjögren’s syndrome, n=29) and others (Behçet syndrome, Henoch-Schönlein purpura, polyarteritis nodosa, Raynaud phenomenon, acute rheumatic fever, and cryoglobulinemic vasculitis, n=23). The TRAQ results according to the diseases are given in Table 1. The results according to sex are given in Figure 1. Females had higher scores than males in tracking health issues (2.65±1.02 vs. 2.31±1.11, p=0.005) and overall TRAQ score (4.31±0.326 vs. 4.22±0.360, p=0.02). The TRAQ results according to the transition age and age at TRAQ administration are given in Table 2. Conclusion: Tracking health issues was the weakest domain in our cohort irrespective of other factors. Females performed better than males in overall TRAQ score. The transition age, the age at TRAQ administration or the diagnosis didn’t affect the overall TRAQ score. Thus, initiating the transition period earlier can be recommended due to the fact that a later transition did not necessarily lead to better outcomes in self-management. Assessing the abilities after the transition in addition to pre-transition period can be a good first step to address the needs of the patients with rheumatologic diseases.
  • Placeholder
    Publication
    Discrepancy between fingertip glucose levels and HbA1c in an adolescent with diabetes: a fake logbook or pseudohypoglycemia?
    (AVES, 2023) Yeşiltepe Mutlu, Rahime Gül; Hatun, Şükrü; Eviz, Elif; Yıldız, Amra Adrovic; Gökçe, Tuğba; Can, Ecem; Faculty Member; Faculty Member; Researcher; Doctor; Doctor; Nurse; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; N/A; N/A; Koç University Hospital; Koç University Hospital; Koç University Hospital; 153511; 153504; 327618; N/A; N/A; N/A
    N/A